Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.570
+0.068 (13.51%)
Nov 7, 2024, 4:00 PM EST - Market closed
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for UNCY stock have an average target of 5.13, with a low estimate of 2.50 and a high estimate of 9.00. The average target predicts an increase of 800.32% from the current stock price of 0.57.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 9, 2024.
Analyst Ratings
The average analyst rating for UNCY stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +338.75% | Oct 9, 2024 |
| Benchmark | Benchmark | Buy Reiterates $3 | Buy | Reiterates | $3 | +426.50% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +338.75% | Sep 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4.5 → $2.5 | Strong Buy | Maintains | $4.5 → $2.5 | +338.75% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4.5 | Strong Buy | Reiterates | $4.5 | +689.75% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
n/a
from 675.00K
Revenue Next Year
33.15M
EPS This Year
-0.74
from -1.28
EPS Next Year
-0.20
from -0.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 123.4M | 636.2M | ||
| Avg | n/a | 33.1M | 327.7M | ||
| Low | n/a | 2.2M | 21.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,819.5% | ||
| Avg | - | - | 888.7% | ||
| Low | - | - | -34.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.44 | 0.68 | 1.94 | ||
| Avg | -0.74 | -0.20 | 1.04 | ||
| Low | -1.09 | -0.46 | -0.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.